Introduction
============

Chlamydia is the most common sexually transmitted infection diagnosed and treated in the United Kingdom,[@ref1] with the highest rates in young people under the age of 25 years. It is often asymptomatic but can have serious sequelae if left untreated. In women, ascending infection causes pelvic inflammatory disease with potential complications of infertility and ectopic pregnancy. *Chlamydia trachomatis* can infect the urethra or endocervix, or both. Studies looking at sites of chlamydia infection in women found chlamydia present in both urethra and endocervix in 73-76%, endocervix only in 15-16%, and urethra only in 10-11%.[@ref2] [@ref3] The optimal diagnostic sample must be able to detect the maximum number of infected people. Also, as up to 70% of infected females can be asymptomatic, it is important that diagnostic tests have good sensitivity and specificity at detecting chlamydia in women both with and without symptoms.

Nucleic acid amplification tests are the "gold standard" for *C trachomatis* detection because of their high sensitivity and specificity. With these tests, numerous studies have shown that non-invasively obtained samples are as accurate as those obtained from the urethra and endocervix.[@ref4] For women without symptoms, non-invasive samples eliminate some of the barriers to screening for chlamydia as they require no examination and are clearly preferred by patients.[@ref5] [@ref6] The non-invasive samples used in women are first-catch urine samples or self collected vulvovaginal swabs. Evidence suggests that self collected vulvovaginal swabs have the better sensitivity, probably because they collect more material from the two potential sites of infection.[@ref7] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12]

The Gen-Probe Aptima Combo-2 assay uses transcription mediated amplification and automatically tests for both chlamydia and gonorrhoea on each sample at no extra cost compared with testing for one pathogen. However, only one swab can be included in each assay tube. Before switching to Aptima Combo-2, our practice in testing women who needed an examination because they had symptoms had been to place swabs from both the urethra and endocervix in the same transport medium for analysis by our previous assay. On transferring to the Aptima Combo-2 assay, we needed to choose between endocervical and vulvovaginal sampling. Most studies have shown that the two samples are equivalent,[@ref4] [@ref7] [@ref10] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19] suggesting that, when a woman is undergoing an examination, an endocervical swab would be preferable on the assumption that it is superior for detecting low chlamydial load in the endocervix (which if missed could leave women at risk of ascending infection). However, one study found vulvovaginal swabs to be significantly more sensitive than endocervical swabs (81% *v* 65%), although the authors commented that the sensitivity of the endocervical swabs was lower than in previously published studies.[@ref9] Hence, it remains unclear which is the optimum sample in women requiring examination.

As part of a study comparing self taken vulvovaginal swabs with clinician taken urethral and endocervical swabs for the detection of gonorrhoea,[@ref20] we were able to evaluate the diagnostic accuracy of self taken vulvovaginal swabs versus clinician taken endocervical swabs for the detection of chlamydia, using the Aptima Combo-2 assay.

Methods
=======

The full methods for the study are described elsewhere.[@ref20] Women aged ≥16 years who presented to the Centre for Sexual Health at Leeds for a new visit were invited to participate. Exclusion criteria were having taken antibiotics in the preceding 28 days and being unable or unwilling to take a vulvovaginal swab or to have the standard examination and swabs performed by a clinician. We collected details of the women's age, ethnicity, history of sexually transmitted infections, and being in contact with a sexually transmitted infection. During the medical history, symptoms in keeping with a bacterial sexually transmitted infection (vaginal discharge, dysuria, intermenstrual or postcoital bleeding, deep dyspareunia, and lower abdominal pain) were recorded. During the examination the presence of cervicitis and pain or tenderness on bimanual pelvic examination in keeping with a clinical diagnosis of pelvic inflammatory disease were noted.

The self taken vulvovaginal swab was taken before examination. The women were then examined, and the clinician took an endocervical sample. Consequently, each woman had samples for chlamydia taken from two different sites, the vulvovagina and endocervix, and these were both analysed for *C trachomatis* by means of the Aptima Combo-2 assay. The assays were performed at the Department of Microbiology by accredited laboratory staff. The vulvovaginal swabs and endocervical samples were assayed according to the manufacturer's instructions (Gen-Probe, San Diego CA, USA). The assay employs transcription mediated amplification technology in which rRNA target molecules from *C trachomatis* are isolated and specific regions are amplified by using a separate capture oligomer and a unique set of primers.

The cut-off values for the chlamydia results were determined by Tigris software for each run. The results of the initial Aptima Combo-2 assay were therefore positive, equivocal, or negative for *C trachomatis.* Positive or equivocal tests were further analysed using the Aptima CT mono-specific platform assay, which has a different target to the Aptima Combo-2. The samples were only reported as clinically positive if confirmed as positive by the Aptima CT. This algorithm of repeat testing for confirmation is currently the suggested national standard operating procedure in England.[@ref21] A positive or equivocal Aptima Combo-2 assay unconfirmed by Aptima CT was reported as indeterminate. A patient was considered to have *C trachomatis* infection if an endocervical or vulvovaginal swab gave at least one positive Aptima Combo-2 test result that was confirmed by the Aptima CT mono-specific platform test. As the cut-off values for the chlamydia results were determined by the Tigris software for each run, the results of these could not be influenced by the laboratory staff.

Statistical analysis
--------------------

We used the Mann Whitney U test to determine any associations between the presence of *C trachomatis* and age and the χ^2^ test to determine associations between *C trachomatis* and the categorical variables. The overall sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the Aptima Combo-2 assay with an endocervical swab and the Aptima Combo-2 assay with a vulvovaginal swab. These analyses were also performed for women with and without symptoms. Any differences between sensitivities were compared using McNamar's test on paired samples.

Results
=======

Participants
------------

Full demographic data and infection status were available for 3973 women recruited by 42 different clinicians, both doctors and nurses, between March 2009 and January 2010. The participants' mean age was 25 years (range 16--59), and self reported ethnicity was 80% white (n=3171), 9% black (362), 7% mixed (297), and 4% other (143). A previous diagnosis of sexually transmitted infection was reported in 1478 (37%), and 292 (7%) reported contact with a partner recently diagnosed with a sexually transmitted infection. At least one symptom suggestive of a bacterial sexually transmitted infection was reported by 1671 (42%) of the participants. A clinical diagnosis of cervicitis was made in 218 (5%), and 169 (4%) had a clinical diagnosis of pelvic inflammatory disease.

In all, 410 of the 3973 women had *C trachomatis* infection (prevalence 10.3%). The factors associated with having chlamydia are shown in table 1[](#tbl1){ref-type="table"}. Fifty five (13.4%) of the women with chlamydia were co-infected with *Neisseria gonorrhoeae*, leaving 355 women with chlamydia but no gonorrhoea. In total, 100 of the 3973 women were infected with gonorrhoea (prevalence 2.5%), leaving 3518 women (88.5%) who were chlamydia and gonorrhoea negative. As gonorrhoea is more likely to cause symptoms and signs suggestive of a bacterial sexually transmitted infection, the data have been analysed including and excluding the women infected with gonorrhoea (table 1[](#tbl1){ref-type="table"}).

###### 

 Factors associated with *Chlamydia trachomatis*infection among 3973 women recruited at a sexual health centre. Values are numbers (percentages) of women unless stated otherwise

                                                                       Positive for chlamydia (n=410)   Negative for chlamydia (n=3563)   Chlamydia prevalence (%)   Odds ratio (95% CI) for infection\*   P value\*
  -------------------------------------------------------------------- -------------------------------- --------------------------------- -------------------------- ------------------------------------- -----------
  **Including women infected with *Neisseria gonorrhoeae* (n=3973)**                                                                                                                                       
  Mean age (years)                                                     22                               25                                10.3                                                             \<0.0001
  Symptoms of STI                                                      218 (53)                         1453 (41)                         13.0                       1.65 (1.34 to 2.03)                   \<0.0001
  Previous STI                                                         151 (37)                         1327 (37)                         10.2                       0.98 (0.79 to 1.22)                   0.91
  Contact of person with STI                                           104 (25)                         188 (5)                           35.6                       6.10 (4.63 to 8.03)                   \<0.0001
  Cervicitis                                                           76 (19)                          142 (4)                           34.9                       5.48 (4.01 to 7.48)                   \<0.0001
  Pelvic inflammatory disease                                          40 (10)                          129 (4)                           23.7                       2.88 (1.95 to 4.23)                   \<0.0001
  Ethnicity:                                                                                                                                                                                               
   White                                                               335 (82)                         2836 (80)                         10.6                       1.15 (0.87 to 1.50)                   0.35
   Black                                                               30 (7)                           332 (9)                           8.3                        0.77 (0.51 to 1.15)                   0.21
   Mixed                                                               43 (10)                          254 (7)                           14.5                       1.53 (1.07 to 2.17)                   0.018
   Other                                                               2 (\<1)                          141 (4)                           1.4                        0.12 (0.02 to 0.49)                   0.0006
  **Excluding women infected with *Neisseria gonorrhoeae* (n=3873)**                                                                                                                                       
  No of women                                                          355                              3518                                                                                               
  Mean age (years)                                                     22                               25                                9.2                                                              \<0.0001
  Symptoms of STI                                                      187 (53)                         1427 (41)                         11.6                       1.63 (1.30 to 2.04)                   \<0.0001
  Previous STI                                                         130 (37)                         1302 (37)                         9.1                        0.99 (0.78 to 1.25)                   0.98
  Contact of person with STI                                           88 (25)                          178 (5)                           33.1                       6.18 (4.61 to 8.30)                   \<0.0001
  Cervicitis                                                           59 (17)                          137 (4)                           30.1                       4.92 (3.50 to 6.91)                   \<0.0001
  Pelvic inflammatory disease                                          33 (9)                           122 (3)                           21.3                       2.85 (1.87 to 4.33)                   \<0.0001
  Ethnicity†:                                                                                                                                                                                              
   White                                                               301 (85)                         2812 (80)                         9.7                        1.40 (1.03 to 1.91)                   0.03
   Black                                                               25 (7)                           322 (9)                           7.2                        0.73 (0.46 to 1.13)                   0.16
   Mixed                                                               27 (7)                           244 (7)                           10.0                       1.03 (0.67 to 1.59)                   0.96
   Other                                                               2 (\<1)                          140 (4)                           1.4                        0.13 (0.02 to 0.54)                   0.002

STI=sexually transmitted infection.

\*Mean ages compared by Mann-Whitney U test, all other factors compared by Pearson's χ^2^ test with Yates correction.

†White women compared with non-white groups combined. Non-white groups compared with white women.

In the whole cohort, women with chlamydia, were significantly more likely to be of mixed ethnicity, to be younger, to have symptoms suggestive of a bacterial sexually transmitted infection, to be a contact of a sexually transmitted infection, and to be clinically diagnosed as having cervicitis and pelvic inflammatory disease, irrespective of whether they were co-infected with gonorrhoea. However, when those infected with gonorrhoea are removed, women of white ethnicity were significantly more likely to have chlamydia compared with non-white women. Women of "other" ethnic origin were significantly less likely to have chlamydia compared with white women irrespective of whether they were co-infected with gonorrhoea.

Test sensitivities and specificities
------------------------------------

Some test results were missing because of problems with sample collection: 29 of the endocervical swabs taken by clinicians could not be processed because of staff errors in labelling, and 77 of the self taken vulvovaginal swabs could not be processed because of participant errors with the sample tube or staff errors in labelling. This meant that 106 (2.7%) of the women recruited had to be removed before statistical analysis with the paired McNemar's test. Table 2[](#tbl2){ref-type="table"} shows the test results for the 3867 women with complete paired results. Of these, 396 (10.2%) were positive for chlamydia. The sensitivities of the clinician taken endocervical swabs and self taken vulvovaginal swabs were 88% and 97% respectively (P\<0.00001).

###### 

 Comparison of self taken vulvovaginal swabs with clinician taken endocervical swabs as diagnostic samples for detection of *Chlamydia trachomatis* infection among 3867 women recruited at a sexual health centre. Values are numbers of women unless stated otherwise

                                                                                      Chlamydia infection status   Total   \% Sensitivity (95% CI)   P value\*       
  ----------------------------------------------------------------------------------- ---------------------------- ------- ------------------------- --------------- -----------
  **Whole cohort**                                                                                                                                                   
  Endocervical swab:                                                                                                                                 88 (85 to 91)   \<0.00001
   Positive                                                                           350                          0       350                                       
   Negative                                                                           46                           3471    3517                                      
   Total                                                                              396                          3471    3867                                      
  Vulvovaginal swab:                                                                                                                                 97 (95 to 98)   
   Positive                                                                           384                          2       386                                       
   Negative                                                                           12                           3469    3481                                      
   Total                                                                              396                          3471    3867                                      
  **Women with symptoms suggestive of bacterial sexually transmitted infection**                                                                                     
  Endocervical swab:                                                                                                                                 88 (83 to 92)   0.0008
   Positive                                                                           187                          0       187                                       
   Negative                                                                           26                           1421    1447                                      
   Total                                                                              213                          1421    1634                                      
  Vulvovaginal swab:                                                                                                                                 97 (93 to 98)   
   Positive                                                                           206                          1       207                                       
   Negative                                                                           7                            1420    1427                                      
   Total                                                                              213                          1421    1634                                      
  **Women without symptoms suggestive of bacterial sexually transmitted infection**                                                                                  
  Endocervical swab:                                                                                                                                 89 (84 to 93)   0.0025
   Positive                                                                           163                          0       163                                       
   Negative                                                                           20                           2050    2070                                      
   Total                                                                              183                          2050    2233                                      
  Vulvovaginal swab:                                                                                                                                 97 (94 to 99)   
   Positive                                                                           178                          1       179                                       
   Negative                                                                           5                            2049    2054                                      
   Total                                                                              183                          2050    2233                                      
  **Women suitable for asymptomatic screen**                                                                                                                         
  Endocervical swab:                                                                                                                                 89 (81 to 95)   0.2668
   Positive                                                                           68                           0       68                                        
   Negative                                                                           8                            1271    1279                                      
   Total                                                                              76                           1271    1347                                      
  Vulvovaginal swab:                                                                                                                                 95 (87 to 98)   
   Positive                                                                           72                           1       73                                        
   Negative                                                                           4                            1270    1274                                      
   Total                                                                              76                           1271    1347                                      

\*Endocervical swab compared with vulvovaginal swab.

Only 10 (0.13%) of the 7734 chlamydia samples were reported as indeterminate, six vulvovaginal swabs and four endocervical swabs. Of the six indeterminate vulvovaginal swab results, three were positive with the Aptima Combo-2 assay but unconfirmed by the Aptima CT assay. Two of these were classified as false positives as the respective endocervical results were negative, and one was classified as a true positive as the respective endocervical result was positive. The remaining three indeterminate vulvovaginal swab results were equivocal with Aptima Combo-2 and unconfirmed with Aptima CT. Two of these had negative endocervical results and so were classified as true negatives, and the other had a positive endocervical result and was classified as a false negative. Of the four endocervical swabs that gave indeterminate results, two had positive Aptima Combo-2 results that were unconfirmed by Aptima CT. As the respective vulvovaginal swabs were positive, they were classified as true positives. The other two had equivocal Aptima Combo-2 results that were unconfirmed by Aptima CT. As the vulvovaginal swabs were negative, they were classified as true negatives. Table 3[](#tbl3){ref-type="table"} shows the sensitivities, specificities, positive predictive values, and negative predictive values for the Aptima Combo-2 assay.

###### 

 Sensitivities, specificities, and positive and negative predictive values of testing for *Chlamydia trachomatis* infection with self taken vulvovaginal swabs or with clinician taken endocervical swabs as diagnostic samples among 3867 women recruited at a sexual health centre. Values are percentages

                                                                                      Sensitivity (95% CI)   Specificity (95% CI)   Predictive value   
  ----------------------------------------------------------------------------------- ---------------------- ---------------------- ------------------ ------
  **Whole cohort**                                                                                                                                     
  Endocervical swab                                                                   88 (85 to 91)          100 (99.9 to 100)      100                98.7
  Vulvovaginal swab                                                                   97 (95 to 98)          99.9 (99.8 to 100)     99.5               99.7
  **Women with symptoms suggestive of bacterial sexually transmitted infection**                                                                       
  Endocervical swab                                                                   88 (83 to 92)          100 (99.7 to 100)      100                98.2
  Vulvovaginal swab                                                                   97 (93 to 98)          99.9 (99.6 to 100)     99.5               99.5
  **Women without symptoms suggestive of bacterial sexually transmitted infection**                                                                    
  Endocervical swab                                                                   89 (84 to 93)          100 (99.8 to 100)      100                99.0
  Vulvovaginal swab                                                                   97 (94 to 99)          99.9 (99.7 to 100)     99.4               99.8
  **Women suitable for asymptomatic screen**                                                                                                           
  Endocervical swab                                                                   89 (81 to 95)          100 (99.7 to 100)      100                99.4
  Vulvovaginal swab                                                                   95 (87 to 98)          99.9 (99.6 to 100)     98.6               99.7

Diagnostic accuracy of tests in women with and without symptoms
---------------------------------------------------------------

At least one symptom suggestive of a bacterial sexually transmitted infection was reported by 1634 (42%) of the participants with complete paired results. Of these, 213 (13%) women were infected with chlamydia. The sensitivities of clinician taken endocervical swabs and self taken vulvovaginal swabs were 88% (187/213) and 97% (206/213) respectively (P=0.0008).

There were 2233 (58%) women who did not have symptoms suggestive of a bacterial sexually transmitted infection, 183 (8%) of whom were infected with chlamydia. The sensitivities of clinician taken endocervical swabs and self taken vulvovaginal swabs were 89% (163/183) and 97% (178/183) respectively (P=0.0025).

There were 1347 women (35%) who would have been suitable for an "asymptomatic screen"---that is, they did not have any symptoms suggestive of a bacterial sexually transmitted infection and did not require examination for any other reason (such as symptoms of genital skin pathology). Of these, 76 (5.6%) had chlamydia infection. The sensitivities of clinician taken endocervical swabs and self taken vulvovaginal swabs were 89% (68/76) and 95% (72/76) respectively (P=0.27).

Discussion
==========

This is the first study to show that vulvovaginal swabs analysed by Aptima Combo-2 are significantly better at detecting *C trachomatis* than endocervical swabs in women with and without symptoms of a sexually transmitted infection. The overall sensitivities were 97% for vulvovaginal swabs and 88% for endocervical swabs, meaning that endocervical swabs diagnosed 9% fewer infections, missing one in every 11 cases of chlamydia. One previous study also found vulvovaginal swabs to be significantly more sensitive than endocervical swabs (at 81% versus 65% respectively), but the authors commented that the sensitivity of the endocervical swabs was lower than in previously published studies, which may have been due to a different laboratory being used for their analysis.[@ref9] Some other studies have reported higher (but non-significant) chlamydia sensitivities with vulvovaginal swabs compared with endocervical swabs.

We have identified 11 published papers where there are comparisons between vulvovaginal swabs and endocervical swabs using nucleic acid amplification tests for the detection of chlamydia.[@ref7] [@ref9] [@ref10] [@ref11] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19] One included a comparison using two different nucleic acid amplification tests, making 12 comparisons in total.[@ref19] Two of the comparisons found a higher sensitivity with the endocervical swabs, with differences of 1.8%[@ref15] and 0.6%,[@ref11] whereas 10 found a higher sensitivity with the vulvovaginal swabs, with a median of 5.1% difference and a range of 1.2--16.0%.[@ref7] [@ref9] [@ref10] [@ref13] [@ref14] [@ref16] [@ref17] [@ref18] [@ref19] Exact data were available in nine of the 11 papers.[@ref9] [@ref10] [@ref11] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] [@ref18] Combining the results, the endocervical swabs diagnosed chlamydia in 772/892 (86.5%) and the vulvovaginal swabs diagnosed chlamydia in 824/886 (93.0%), a difference of 6.5%. As reported in other studies, we found excellent specificity using both the endocervical swabs (100%) and the vulvovaginal swabs (99.9%) for the detection of chlamydia with the Aptima Combo-2 assay.[@ref19] [@ref22]

We think the difference in sensitivity between endocervical swabs and vulvovaginal swabs is probably due to missed urethral infections when the endocervical site alone is sampled. This theory is supported by a study that investigated use of using first-catch urine samples in addition to endocervical swabs; it found that endocervical swabs tested by Aptima Combo-2 detected 99.4% of cervical *C trachomatis* infections but only 92.1% of the total *C trachomatis* infections because some were detected only with first-catch urine. This reduction in sensitivity was greater when testing for chlamydia than for gonorrhoea.[@ref22] Also, a study comparing sensitivities of endocervical swabs, vulvovaginal swabs, and first-catch urine samples, separately or in combination, for the detection of chlamydia found the separate endocervical swab, vulvovaginal swab, and first-catch urine samples detected 65%, 81%, and 72% respectively, whereas the endocervical swab plus first-catch urine detected 86%, the endocervical and vulvovaginal swabs detected 91%, and the vulvovaginal swab plus first-catch urine detected 94%.[@ref9]

Implications of study results
-----------------------------

The higher chlamydia diagnostic sensitivity with vulvovaginal swabs in our study was seen in all women irrespective of whether they had symptoms suggestive of a bacterial sexually transmitted infection. In those who would not routinely require a genital examination, endocervical swabs and vulvovaginal swabs were equivalent. Our study therefore confirms the previous evidence that in women without symptoms, and for those who do not require a speculum examination, the sample of choice is a self taken vulvovaginal swab, which is an appropriate sample to test for both chlamydia and gonorrhoea.[@ref20] In women with symptoms the sensitivity of chlamydia detection by means of vulvovaginal swabs was significantly higher than for endocervical swabs (97% versus 88%). Using endocervical samples rather than vulvovaginal swabs would have missed 9% of infections, or one in every 11 cases of chlamydia. These findings give a clear indication that the best single sample for chlamydia detection in women with symptoms is the vulvovaginal swab. Therefore, in women with symptoms, where a speculum examination would be normal practice, we recommend either a self taken vulvovaginal swab before the examination or a clinician taken vulvovaginal swab before the speculum insertion. These have been shown to be equivalent in sensitivity,[@ref10] but the clinician taken sample has the advantage that patient errors in collection are eliminated.

The associations of chlamydia infection with younger age and mixed ethnicity, and decreased likelihood in women of "other" ethnicity are in keeping with data from the National Chlamydia Screening Programme (NCSP), which found that chlamydia disproportionately affects young adults and black or mixed ethnic groups.[@ref23] However, some women with chlamydia (13.4% in our study) are co-infected with gonorrhoea, which is also associated with black or mixed ethnicity.[@ref20] Interestingly when those with gonorrhoea were removed from our data, white women were significantly more likely to have chlamydia compared with non-white women. Our findings suggest that when assessing any association between ethnicity and chlamydia infection, gonorrhoea is a confounding factor. The NCSP data do not identify those with and without gonorrhoea, as chlamydia status is tested but not necessarily gonorrhoea status. From our study findings, we suggest white ethnicity should be considered as a risk factor for chlamydia infection in the UK.

Strengths and limitations of study
----------------------------------

The strengths of our study include its large number of participants with 42 different clinicians collecting the samples---as such, it is reflective of real clinical situations. The population attending the Centre for Sexual Health at Leeds is similar to many other clinic populations, both in the UK and in other countries, meaning our findings are widely applicable.

The limitations are that, although there were a large number of participants, this was a single centre study. The order of the samples was not randomised or rotated. The self taken vulvovaginal swab was collected before the clinician taken endocervical swab. In other published studies comparing vulvovaginal swabs with endocervical samples, the vulvovaginal swab was performed first, before the insertion of a vaginal speculum.[@ref7] [@ref9] [@ref10] [@ref14] [@ref16] [@ref17] [@ref18] [@ref19] As the sites for these samples are different, there is no reason to suspect that taking the vulvovaginal swab would affect the sensitivity of the endocervical sample. However, as part of the diagnostic comparisons for gonorrhoea in this study,[@ref20] all participants had an endocervical swab taken for gonorrhoea culture, which was performed before the endocervical swab for Aptima Combo-2 assay in view of the reduced sensitivity of culture.

It could be argued that taking the endocervical culture sample first reduces the sensitivity of the endocervical sample for nucleic acid amplification tests, which might account for the lower sensitivity in our endocervical samples compared with the vulvovaginal swabs. We believe this is unlikely, as a comparison of endocervical swabs and cytobrushes (using a less sensitive test than a nucleic acid amplification test) showed no difference in the rate of detection of *C trachomatis* irrespective of the order in which they were performed.[@ref24]

Further limitations are that negative Aptima Combo-2 tests were not repeated, so we could have missed some false negative results. This is unlikely, however, as each participant had two different samples analysed for chlamydia. As we assessed only one nucleic acid amplification test, our results cannot necessarily be extrapolated to other such tests. The sensitivity and specificity of different nucleic acid amplification tests for chlamydia detection can vary, as reported in a systematic review.[@ref4]

Conclusions
-----------

The optimal diagnostic sample must be able to detect the maximum number of infected people, and we found that vulvovaginal swabs analysed by Aptima Combo-2 for chlamydia infection were significantly more sensitive than endocervical swabs, which missed 9% of cases in routine clinical practice. Therefore, in women who do not require a speculum examination the sample of choice is a self taken vulvovaginal swab. This has benefits for the patient in that a genital examination is avoided, and it has health economic benefits in that clinician time and equipment use is reduced. For women with symptoms, we would recommend either a self taken vulvovaginal swab before the examination or a clinician taken vulvovaginal swab before speculum insertion.

### What is already known on this topic

1.  The optimal diagnostic sample for *Chlamydia trachomatis* detection should detect the maximum number of infected people

2.  In women without symptoms the sample of choice is a self taken vulvovaginal swab, but it is not clear whether a vulvovaginal swab or an endocervical swab is the optimum sample in women with symptoms requiring speculum examination

### What this study adds

1.  In this study of women attending a sexual health centre vulvovaginal swabs were significantly better at detecting chlamydia infection than endocervical swabs among women with symptoms of a sexually transmitted infection

2.  In these cases, using endocervical samples rather than vulvovaginal swabs would have missed 9% of infections, or 1 in 11 cases of chlamydia infection

3.  Women with symptoms should have either a self taken vulvovaginal swab before examination or a clinician taken vulvovaginal swab before speculum insertion
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